Search: WFRF:(Magistretti P. J.)
> (2020-2022) >
Targeting CXCR1/2 D...
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes
-
- Maffi, P. (author)
- IRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy
-
- Lundgren, T. (author)
- Karolinska Institutet
-
- Tufveson, Gunnar (author)
- Uppsala universitet,Transplantationskirurgi
-
show more...
-
- Rafael, E. (author)
- Skane Univ Hosp, Malmo, Sweden
-
- Shaw, J. A. M. (author)
- Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England;Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England,IRCCS Osped San Raffaele, Milan, Italy
-
- Liew, A. (author)
- Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England;Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England
-
- Saudek, F. (author)
- Inst Clin & Expt Med, Prague, Czech Republic
-
- Witkowski, P. (author)
- Univ Chicago Med, Transplantat Inst, Chicago, IL USA
-
- Golab, K. (author)
- Univ Chicago Med, Transplantat Inst, Chicago, IL USA
-
- Bertuzzi, F. (author)
- Osped Niguarda Ca Granda, Milan, Italy
-
- Gustafsson, Bengt, 1946 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi,Institute of Neuroscience and Physiology, Department of Physiology,Univ Gothenburg, Gothenburg, Sweden
-
- Daffonchio, L. (author)
- Dompe Farmaceut SpA, Dept Res & Dev, Milan, Italy
-
- Ruffini, P. A. (author)
- Dompe Farmaceut SpA, Dept Res & Dev, Milan, Italy
-
- Piemonti, L. (author)
- IRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy
-
- Nano, R. (author)
- IRCCS Osped San Raffaele, Milan, Italy
-
Mercalli, A. (author)
-
- Lampasona, V. (author)
- IRCCS Osped San Raffaele, Milan, Italy
-
- Magistretti, P. (author)
- IRCCS Osped San Raffaele, Milan, Italy
-
- Sordi, V. (author)
- IRCCS Osped San Raffaele, Milan, Italy
-
- Antonio, S. (author)
- IRCCS Osped San Raffaele, Milan, Italy
-
- Antonioli, B. (author)
- Osped Niguarda Ca Granda, Milan, Italy
-
- Galuzzi, M. (author)
- Osped Niguarda Ca Granda, Milan, Italy
-
- Tosca, M. C. (author)
- Osped Niguarda Ca Granda, Milan, Italy
-
- De Carlis, L. (author)
- Osped Niguarda Ca Granda, Milan, Italy
-
- Colussi, G. (author)
- Osped Niguarda Ca Granda, Milan, Italy
-
- Korsgren, Olle (author)
- Uppsala universitet,Klinisk immunologi
-
- Pollard, H. (author)
- Skane Univ Hosp, Malmo, Sweden
-
show less...
-
(creator_code:org_t)
- 2020-02-04
- 2020
- English.
-
In: Diabetes Care. - : American Diabetes Association. - 0149-5992 .- 1935-5548. ; 43:4, s. 710-718
- Related links:
-
https://care.diabete...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.2...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients. RESEARCH DESIGN AND METHODS A phase 3, multicenter, randomized, double-blind, parallel-assignment study () was conducted in recipients of islet allotransplants randomized (2:1) to reparixin or placebo in addition to immunosuppression. Primary outcome was the area under the curve (AUC) for C-peptide during the mixed-meal tolerance test at day 75 +/- 5 after the first and day 365 +/- 14 after the last transplant. Secondary end points included insulin independence and standard measures of glycemic control. RESULTS The intention-to-treat analysis did not show a significant difference in C-peptide AUC at both day 75 (27 on reparixin vs. 18 on placebo, P = 0.99) and day 365 (24 on reparixin vs. 15 on placebo, P = 0.71). There was no statistically significant difference between treatment groups at any time point for any secondary variable. Analysis of patient subsets showed a trend for a higher percentage of subjects retaining insulin independence for 1 year after a single islet infusion in patients receiving reparixin as compared with patients receiving placebo (26.7% vs. 0%, P = 0.09) when antithymocyte globulin was used as induction immunosuppression. CONCLUSIONS In this first double-blind randomized trial, islet transplantation data obtained with reparixin do not support a role of CXCR1/2 inhibition in preventing islet inflammation-mediated damage.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- beta-cell function
- antiinflammatory strategies
- inhibition
- induction
- immunosuppression
- engraftment
- survival
- regimen
- Endocrinology & Metabolism
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Maffi, P.
-
Lundgren, T.
-
Tufveson, Gunnar
-
Rafael, E.
-
Shaw, J. A. M.
-
Liew, A.
-
show more...
-
Saudek, F.
-
Witkowski, P.
-
Golab, K.
-
Bertuzzi, F.
-
Gustafsson, Beng ...
-
Daffonchio, L.
-
Ruffini, P. A.
-
Piemonti, L.
-
Nano, R.
-
Mercalli, A.
-
Lampasona, V.
-
Magistretti, P.
-
Sordi, V.
-
Antonio, S.
-
Antonioli, B.
-
Galuzzi, M.
-
Tosca, M. C.
-
De Carlis, L.
-
Colussi, G.
-
Korsgren, Olle
-
Pollard, H.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Diabetes Care
- By the university
-
University of Gothenburg
-
Uppsala University
-
Karolinska Institutet